Is AMETEK Stock Outperforming the S&P 500? AMETEK has outperformed the S&P 500 over the past year, and analysts are moderately optimistic about the stock’s prospects. Barchart · Sep 10
Johnson & Johnson Stock: Is JNJ Outperforming the Consumer Staples Sector? Johnson & Johnson has outpaced the consumer staples sector over the past year, while analysts remain moderately bullish on the stock’s prospects. Barchart · Aug 29
Entero Healthcare shares gain 15% in 2 days after Prashant Jain’s 3P Investment picks stake in block deal Entero Healthcare Solutions shares rose sharply after Prashant Jain-owned 3P Investment Managers acquired a 2.5% stake in the company through open market transactions. The shares were bought from Prasid Uno Family Trust at Rs 1,377.8 apiece, according to stock exchange data. The Economic Times · Aug 25
AMETEK Stock: Is Wall Street Bullish or Bearish? AMETEK has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects. Barchart · Aug 13
Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street Abbott's Q2 results show solid organic growth, better-than-expected margins, and improved earnings guidance, easing concerns over the Exact Sciences acquisition and boosting ABT shares. MarketBeat · Jul 16
Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity Johnson & Johnson's post-earnings pullback follows a revenue and EPS beat, raised guidance, and analyst price target increases, with talc litigation remaining the key risk to watch. MarketBeat · Jul 15
Silicon Valley veteran Rahul Roy plans summit to get Bengal AI-ready Silicon Valley veteran Rahul Roy is organizing Confluence2027, a summit in San Jose from April 9-11, 2027, aimed at bridging West Bengal with the global tech hub. Focusing on AI, medtech, and economic development, the event seeks to address critical skills gaps and integrate AI innovations into the state's education. The Times of India · Jul 2
Health services, medical education expansion to be driven by modern tech: Yogi Adityanath Uttar Pradesh Chief Minister Yogi Adityanath reviewed health and medical education. He stressed improving treatment quality and expanding services. Medical colleges and nursing institutions will be strengthened with modern technology. Ayushman Yojana support for the poor was highlighted. Efforts are underway to enhance emergency services and control communicable diseases. The Economic Times · May 26
Zydus Lifesciences shares soar 7% to fresh record high after Q4 results. Should you buy, sell or hold? Zydus Lifesciences shares climbed to a new 52-week high. The company reported a 9% rise in net profit and over 16% revenue growth for the January-March quarter. A Rs 1,100 crore share buyback was announced. Analysts from Nomura, Nuvama, Motilal Oswal, and JM Financial shared their views on the company's… The Economic Times · May 20
STERIS Q4 Earnings Call Highlights STERIS (NYSE:STE) reported a stronger fiscal 2026 overall despite a lighter fourth quarter, with executives pointing to record annual revenue, resilient procedure demand and continued pricing gains, while also outlining expectations for mid- to high-single-digit growth in fiscal 2027. Senior Vice P MarketBeat · May 15
Canvas Hacked Update: Who Are the Hackers and How Long Will the LMS Be Down? A cyberattack on the Canvas LMS disrupted access to coursework and exams at major US universities during finals week, with a ransom note from ShinyHunters. International Business Times UK · May 8
From drought to demand: Biotech IPOs roar back with Kailera and Alamar Strong demand for GLP-1 drugs and next-gen diagnostic testing is pulling investors back into life sciences, even as AI soaks up most venture dollars. Fortune · Apr 18
Stryker Cyberattack Sparks Health Sector Alert as Iran-Linked Hackers Target Medtech Firm Serving 150M Patients Learn about the impact on global healthcare operations and the urgent measures being taken to protect patient care and MedTech security International Business Times UK · Mar 12
Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech Sector Johnson & Johnson provides stability through decades of dividend growth while pivoting to high-margin medical technology to outperform the volatile market. MarketBeat · Feb 24
Barchart · Jan 29 1 Dividend King to Buy and Hold Through Any Market In uncertain markets, reliable income matters more than ever. This Dividend King offers exactly that.
inkl · Dec 8, 2025 Why Requirements Management Is Critical in Regulated Device Development In the development of regulated medical devices, adherence to stringent regulatory requirements is not optional but a foundational necessity. Regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others around the world enforce strict guidelines to ensure the safety, efficacy, and reliability…
MarketBeat · Oct 18, 2025 Johnson & Johnson's M&A Strategy Is the Real Story for Investors Johnson & Johnson’s rumored Protagonist buyout demonstrates its proven M&A strategy: divesting low-growth units to fund high-margin, innovative assets.
Benzinga · Oct 3, 2025 AngioDynamics Eyes Growth Despite Tariffs AngioDynamics, Inc. (NASDAQ:ANGO) posted stronger-than-expected first-quarter results across its Med-Tech businesses and lifted its fiscal 2026 guidance.
Benzinga · Oct 2, 2025 What's Fueling The Momentum In AngioDynamics Stock? Shares of AngioDynamics, Inc. (NASDAQ:ANGO) are up Thursday after the biotechnology company raised guidance for four key financial metrics and shared positive sales performance for this past quarter.
Barchart · Sep 24, 2025 Why This Dividend King Still Stands Tall With a strong product portfolio and growth prospects in innovative medicines, this dividend stock is likely to maintain its 63-year streak of dividend increases.
MarketBeat · Sep 16, 2025 3 Dividend Stocks to Hold Through Market Volatility This Fall Interest rate cuts may not decrease market volatility; discover three dividend stocks that can deliver stability, income, and growth during this fall
Barchart · Aug 28, 2025 These 2 Healthcare Stocks Are Even Better Bargain Buys Than UnitedHealth As the healthcare sector lags broader markets, AbbVie’s innovation in immunology and Johnson & Johnson’s MedTech expansion make these dividend giants standout bargains at below-market valuations
MarketBeat · Aug 25, 2025 JNJ Stock Surge Signals Confidence in New Growth Path Johnson & Johnson's strategic shift to a focused pharma and medtech model is fueling growth through a powerful drug pipeline and key acquisitions.
Barchart · Jul 23, 2025 2 Recession-Proof Dividend Stocks to Buy for the Second Half of 2025 These blue-chip stocks offer a rare combination of stability, resilience, and moderate growth.
Benzinga · Jul 17, 2025 Johnson & Johnson Ups Forecast, Beats On EPS—But Wall Street Is Cautious Shares of Johnson Johnson (NYSE:JNJ) are under pressure Thursday, despite a strong second-quarter earnings report.